We are live on ! Find out more
TVRD

Tvardi Therapeutics

165 hedge funds and large institutions have $324M invested in Tvardi Therapeutics in 2022 Q3 according to their latest regulatory filings, with 14 funds opening new positions, 70 increasing their positions, 44 reducing their positions, and 26 closing their positions.

New
Increased
Maintained
Reduced
Closed

87% more call options, than puts

Call options by funds: $1.89M | Put options by funds: $1.01M

59% more repeat investments, than reductions

Existing positions increased: 70 | Existing positions reduced: 44

2% more capital invested

Capital invested by funds: $318M → $324M (+$6.07M)

0.02% less ownership

Funds ownership: 1.8%1.79% (-0.02%)

8% less funds holding

Funds holding: 179165 (-14)

46% less first-time investments, than exits

New positions opened: 14 | Existing positions closed: 26

Holders
165
Holders Change
-14
Holders Change %
-7.82%
% of All Funds
2.84%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
14
Increased
70
Reduced
44
Closed
26
Calls
$1.89M
Puts
$1.01M
Net Calls
+$879K
Net Calls Change
-$2.01M

TVRD Hedge Fund Activity: Q3 2022 in Review

165 of the 5,806 institutional investors tracked by Wall St. Rank reported a position in Tvardi Therapeutics (TVRD) for Q3 2022, worth a combined $324M — up 1.9% from $318M a quarter earlier.

Sellers outnumbered buyers: 26 funds closed out of TVRD and 14 opened new positions — a net loss of 12 holders — while 44 trimmed existing stakes and 70 added.

The largest buyer was ClearBridge Investments, opening a new position worth an estimated $4.4M. The largest seller was Millennium Management, exiting entirely with an estimated $7.11M sold.

  • 165 institutional investors held Tvardi Therapeutics (TVRD) as of Q3 2022, down from 179 in Q2 2022.
  • Funds reported $324M of Tvardi Therapeutics stock for Q3 2022, up 1.9% quarter-over-quarter.
  • 14 funds opened new Tvardi Therapeutics positions in Q3 2022 and 26 closed out, a net change of -12 holders.
  • The largest Tvardi Therapeutics buyer in Q3 2022 was ClearBridge Investments, an estimated $4.4M added.
  • The largest Tvardi Therapeutics seller in Q3 2022 was Millennium Management, an estimated $7.11M sold.

Based on aggregated 13F filings for Q3 2022.